Mobile

A Phase 2 multi centre, double blind, placebo controlled flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004150-51

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to investigate the safety and efficacy of the UK-390,957 individual flexible dose group (including doses up to 10 mg) compared to placebo. Efficacy will be assessed using IELT at Week 8 and adverse events will be summarized by treatment arm.

Critère d'inclusion

  • premature ejaculation

Liens